NCT01248975 - Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma | Biotech Hunter

Enrollment

145

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Asthma

Interventions

DRUG

FP/SAL 250/50mcg BID

DRUG

GSK2190915 200mg QD (AM)

DRUG

GSK2190915 100mg QD (AM)

DRUG

Montelukast 10mg QD (PM)

DRUG

Placebo tablets (2) (AM)

DRUG

Placebo capsule (PM)

Trial Locations (19)

3680

GSK Investigational Site, Kiev

5800

GSK Investigational Site, Pleven

7000

GSK Investigational Site, Rousse

9010

GSK Investigational Site, Varna

49027

GSK Investigational Site, Dnipropetrovsk

49051

GSK Investigational Site, Dnipropetrovsk

61035

GSK Investigational Site, Kharkiv

61037

GSK Investigational Site, Kharkiv

69035

GSK Investigational Site, Zaporizhia

76018

GSK Investigational Site, Ivano-Frankivsk

83099

GSK Investigational Site, Donetsk

15-084

GSK Investigational Site, Bialystok

93-329

GSK Investigational Site, Lodz

33-100

GSK Investigational Site, Tarnów

03680

GSK Investigational Site, Kiev

02091

GSK Investigational Site, Kyiv

02232

GSK Investigational Site, Kyiv

03115

GSK Investigational Site, Kyiv

04107

GSK Investigational Site, Kyiv